Q1 Earnings Estimate for Arvinas Issued By Wedbush

Arvinas, Inc. (NASDAQ:ARVN) – Equities researchers at Wedbush issued their Q1 2026 earnings estimates for shares of Arvinas in a research note issued on Wednesday, November 5th. Wedbush analyst R. Driscoll expects that the company will post earnings of ($0.63) per share for the quarter. Wedbush has a “Neutral” rating and a $9.00 price objective on the stock. The consensus estimate for Arvinas’ current full-year earnings is ($3.81) per share. Wedbush also issued estimates for Arvinas’ Q2 2026 earnings at ($0.65) EPS.

Other research analysts have also recently issued reports about the company. Stephens reduced their price target on Arvinas from $16.00 to $14.00 and set an “overweight” rating for the company in a research report on Thursday, September 18th. Wells Fargo & Company decreased their price objective on shares of Arvinas from $16.00 to $15.00 and set an “overweight” rating for the company in a research report on Thursday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Arvinas in a report on Wednesday, October 8th. HC Wainwright lowered their price target on Arvinas from $24.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, August 7th. Finally, Bank of America downgraded shares of Arvinas from a “buy” rating to a “neutral” rating and set a $10.00 price target on the stock. in a research note on Wednesday, September 24th. Eleven equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $16.34.

Arvinas Trading Down 1.3%

Shares of NASDAQ ARVN traded down $0.13 during trading on Friday, reaching $9.87. 220,376 shares of the company traded hands, compared to its average volume of 2,164,310. The stock has a market cap of $724.58 million, a P/E ratio of -12.19 and a beta of 2.38. The firm’s fifty day simple moving average is $8.77 and its 200 day simple moving average is $7.90. Arvinas has a 12-month low of $5.90 and a 12-month high of $28.70.

Arvinas (NASDAQ:ARVN) last issued its earnings results on Wednesday, November 5th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.27. The firm had revenue of $41.90 million during the quarter, compared to analysts’ expectations of $29.36 million. Arvinas had a negative net margin of 18.73% and a negative return on equity of 9.58%. The firm’s revenue was down 59.1% compared to the same quarter last year. During the same quarter last year, the company posted ($0.68) earnings per share.

Arvinas announced that its board has authorized a share buyback program on Wednesday, September 17th that allows the company to buyback $100.00 million in shares. This buyback authorization allows the company to purchase up to 17.9% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s board of directors believes its stock is undervalued.

Insider Activity at Arvinas

In other news, Director Briggs Morrison acquired 30,000 shares of the firm’s stock in a transaction dated Monday, September 22nd. The shares were bought at an average price of $7.57 per share, with a total value of $227,100.00. Following the acquisition, the director owned 76,021 shares of the company’s stock, valued at $575,478.97. This trade represents a 65.19% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.73% of the company’s stock.

Hedge Funds Weigh In On Arvinas

Hedge funds and other institutional investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Arvinas by 5.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,636 shares of the company’s stock worth $271,000 after buying an additional 2,122 shares in the last quarter. Oxford Asset Management LLP boosted its holdings in Arvinas by 15.5% in the second quarter. Oxford Asset Management LLP now owns 16,705 shares of the company’s stock valued at $123,000 after acquiring an additional 2,242 shares during the last quarter. Nebula Research & Development LLC increased its position in Arvinas by 3.9% in the second quarter. Nebula Research & Development LLC now owns 76,747 shares of the company’s stock worth $565,000 after purchasing an additional 2,910 shares during the period. AlphaQuest LLC raised its holdings in Arvinas by 18.7% during the 2nd quarter. AlphaQuest LLC now owns 19,573 shares of the company’s stock worth $144,000 after purchasing an additional 3,086 shares during the last quarter. Finally, Woodline Partners LP lifted its position in Arvinas by 0.5% during the 1st quarter. Woodline Partners LP now owns 695,945 shares of the company’s stock valued at $4,886,000 after purchasing an additional 3,212 shares during the period. 95.19% of the stock is owned by institutional investors.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.